Novo Nordisk’s semaglutide succeeds in two phase 3a type 2 diabetes trials

This article was originally published here

Novo Nordisk said that oral semaglutide succeeded in two phase 3a trials by registering statistically significantly greater reductions in HbA1c and weight in adults with type 2 diabetes.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply